COMMUNIQUÉS West-GlobeNewswire

CRISPR Therapeutics to Present at the Morgan Stanley 24th Annual Global Healthcare Conference
08/09/2026
ZUG, Switzerland and BOSTON, Sept. 08, 2026 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP) today announced that members of its senior management team will present at the Morgan Stanley 24th Annual Global [...]
Can-Fite Reports Q2 2026 Financial Results and Ongoing Clinical Progress Highlighting Longer-Than-Anticipated Overall Survival in Ongoing Pivotal Phase III Liver Cancer Study
08/09/2026
RAMAT GAN, Israel, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company developing a pipeline of proprietary small molecule drugs targeting oncological [...]
Veru Advances Oral Sabizabulin Following Positive Preclinical Data Showing Potent Anticancer Activity in Human Daraxonrasib (Revolution Medicines’ RASONQUE™) Resistant Pancreatic Cancer into a Planned Phase 2 Clinical Trial
08/09/2026
--New positive preclinical studies show that sabizabulin can overcome drug resistance to daraxonrasib with potent anticancer efficacy (IC50=18.2nM) in daraxonrasib resistant human pancreatic cancer cell line which is a [...]
GRI Bio Presents New Phase 2a Data at ERS 2026 Defining GRI-0621's Mechanism of Action in IPF Across Nine Mechanistic Pillars
08/09/2026
New whole blood RNA sequencing data identified coordinated, consistent change in genes governing immune re-balancing, myofibroblast inhibition, fibrolysis, basement membrane repair, re-epithelialization, antitussive [...]
Dr. Gillian Cannon Joins Lindus Therapeutics’ Board as a Non-Executive Director
08/09/2026
BOSTON, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Lindus Therapeutics , a next-generation drug development company advancing a portfolio of in-licensed assets, has announced the appointment of Dr. Gillian Cannon to its board [...]
Renexxion to Present at H.C. Wainwright 28th Annual Global Investment Conference
08/09/2026
LOS ALTOS, Calif., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Renexxion, Inc. (“Renexxion”), a late-stage clinical biopharmaceutical company building leadership in the development of treatments for GI motility disorders, [...]
CPTx appoints Matt Kane as Chief Financial Officer
08/09/2026
Experienced gene editing and cell therapy pioneer to head financing and strengthen strategic leadership for CPTx non-viral DNA-based in vivo CAR T platform Munich, Germany & San Francisco, California – September 8, [...]
Fortress Biotech to Present at the H.C. Wainwright 28th Annual Global Investment Conference
08/09/2026
MIAMI, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”), an innovative biopharmaceutical company focused on acquiring and advancing assets to enhance long-term value for shareholders [...]
Amwell Receives Letter of Intent from Department of Veterans Affairs to Help Power its Digital Health Infrastructure
08/09/2026
Amwell platform expected to facilitate connected care, improving access and quality of care for the more than nine million Veteran beneficiaries BOSTON, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Amwell ® (NYSE: AMWL), a [...]
Pharvaris Announces Positive Topline Data from CHAPTER-3 Pivotal Study of Deucrictibant XR for Prophylaxis of HAE Attacks
08/09/2026
Primary endpoint met: 83% attack rate reduction versus placebo (p<0.0001) in the first and only prophylaxis Phase 3 study in all three types of HAE 87% attack rate reduction versus placebo observed in people with HAE [...]
Bluejay Diagnostics and Lovell Government Services Announce Partnership to Expand Access to U.S. Federal Healthcare Markets
08/09/2026
Partnership Establishes Federal Distribution and Co-Marketing Framework Across VA, DoD, Military Health Systems and Other Government Healthcare Channels ACTON, Mass. and PENSACOLA, Fla., Sept. 08, 2026 (GLOBE NEWSWIRE [...]
Prana Therapies Announces Positive Phase 1 Results for PRA-216, a Novel IL-4Rα/TSLP Bispecific Antibody, Supporting Its Potential Best-in-Disease Profile and Providing the First Clinical Validation of Prana’s INSPIRE Multispecific Platform
08/09/2026
Rapid, deep, and durable pharmacodynamic activity demonstrated across key Type 2 inflammatory biomarkers, including pSTAT6, TARC, eosinophils, and IgE Extended half-life and 85% subcutaneous bioavailability support the [...]
UK’s MHRA Accepts Biosplice’s Application for Lorecivivint (LOR) in Knee Osteoarthritis and Begins Assessment
08/09/2026
LOR, the first approval-stage drug candidate with disease-modifying potential for osteoarthritis, is now under assessment in the United Kingdom, with a submission to the European Medicines Agency planned for later this [...]
Belite Bio Announces Submission of New Drug Application to the Ministry of Health, Labour, and Welfare in Japan under the Sakigake Designation System for Tinlarebant for the Treatment of Stargardt Disease Type 1
08/09/2026
U.S. Food and Drug Administration accepted the New Drug Application with Priority Review for tinlarebant for the treatment of Stargardt disease type 1; Prescription Drug User Fee Act target action date of February 12, [...]
Pulmovant Announces Positive Results from PHocus Study of Mosliciguat in Patients with Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD) and Unveils Ongoing Phase 3 PHrontier Study
08/09/2026
PHocus met its primary endpoint, demonstrating a clinically meaningful and statistically significant placebo-adjusted reduction in pulmonary vascular resistance (PVR) of -56.3% (p<0.0001) at Week 16, the highest ever [...]
Notice to Convene an Extraordinary General Meeting of Genmab A/S
08/09/2026
Company Announcement Genmab A/S to hold an Extraordinary General Meeting on Wednesday, October 7, 2026 COPENHAGEN, Denmark; September 8, 2026 – Genmab A/S (Nasdaq: GMAB) convenes an Extraordinary General Meeting to be [...]
Roivant Announces Positive Results from PHocus Study of Mosliciguat in Patients with Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD) and Unveils Ongoing Phase 3 PHrontier Study
08/09/2026
PHocus met its primary endpoint, demonstrating a clinically meaningful and statistically significant placebo-adjusted reduction in pulmonary vascular resistance (PVR) of -56.3% (p<0.0001) at Week 16, the highest ever [...]
MediciNova to Participate in Two Investor Conferences in September
08/09/2026
LA JOLLA, Calif., Sept. 08, 2026 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ: MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875 [...]
RadNet, Inc. to Present at the Jefferies Healthcare Services and Technology Conference on September 15, 2026
08/09/2026
LOS ANGELES, Sept. 08, 2026 (GLOBE NEWSWIRE) -- RadNet, Inc. (NASDAQ: RDNT), a national leader in providing high-quality, cost-effective diagnostic imaging services through a network of fully-owned and operated [...]

Pages